MeSH D008224 - follicular lymphoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Acrotech Biopharma | Ibritumomab tiuxetan | Zevalin |  | 2002-02-19 |  |  |
| Bayer | Copanlisib | Aliqopa | 2024-05-13 | 2017-09-14 |  |  |
| Bristol Myers Squibb | Lisocabtagene maraleucel | Breyanzi |  | 2022-04-04 | $400 M | Q2/23-Q1/24 |
| Ceft BioPharma | Ibritumomab tiuxetan | Zevalin |  | 2004-01-16 |  |  |
| Genentech | Obinutuzumab | Gazyva |  | 2013-11-01 |  |  |
| Mosunetuzumab | Lunsumio |  | 2022-12-22 |  |  | |
| Gilead Sciences | Axicabtagene ciloleucel | Yescarta |  | 2018-08-23 | $1,519 M | Q2/23-Q1/24 |
| Krka | Lenalidomide | Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) |  | 2021-02-11 |  |  |
| Lenalidomide | Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) |  | 2021-02-11 |  |  | |
| Lenalidomide | Lenalidomide Krka d.d |  | 2021-02-11 |  |  | |
| Merck Sharp & Dohme | Interferon alfa-2b | IntronA |  | 2000-03-09 |  |  |
| Roche | Obinutuzumab | Gazyvaro |  | 2014-07-22 |  |  |
| Mosunetuzumab | Lunsumio |  | 2022-06-03 |  |  | |
| Secura Bio | Duvelisib | Copiktra |  | 2021-05-19 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
78%108/139
Phase 2
27%37/138
Phase 3
48%28/58
Approved: 12Overall Success rate: 10%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use